Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UHJ9
UPID:
PGAP2_HUMAN
Alternative names:
FGF receptor-activating protein 1
Alternative UPACC:
Q9UHJ9; E9PJG5; H7BXL9; Q6UC77; Q96G66; Q9UF01; Q9Y4N1
Background:
Post-GPI attachment to proteins factor 2, also known as FGF receptor-activating protein 1, plays a crucial role in the lipid remodeling steps of GPI-anchor maturation. This process is essential for the stable expression of GPI-anchored proteins on the cell surface, which are vital for various cellular functions.
Therapeutic significance:
The protein is linked to Hyperphosphatasia with impaired intellectual development syndrome 3, a disorder marked by intellectual disability and poor motor development. This association highlights the protein's potential as a target for therapeutic intervention in treating or managing this genetic condition.